Original articles

Ampullary adenocarcinoma: analysis of the clinicopathological features and prognostic factors

Expand
  • Department of Pathology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China

Received date: 2022-04-08

  Online published: 2022-08-17

Abstract

Objective: To evaluate the clinicopathologic features and prognosis of ampullary adenocarcinoma (AA). Methods: The proportion of AA in patients who underwent pancreaticoduodenectomy were calculated in Ruijin hospital from January 2017 to December 2019. The clinical data and pathological features were analyzed. According to the new histological classification standard in the fifth edition of the World Health Organization classification of digestive system tumors in 2019, AA was reclassified and the risk factors for poor prognosis were analyzed. Results: It revealed that AA account for 6.95%(101/1454) in patients undergone pancreaticoduodenectomies. The median age of onset was 64 years, and the male to female ratio was 46∶55. The proportion of histological sub-types were 19.80%(20/101) for intestinal-type adenocarcinoma, 43.56% (44/101) for pancreatobiliary-type adenocarcinoma and 36.63% (37/101) for tubular adenocarcinoma. Among these 101 patients, 26 patients were lost to follow-up, and the remaining 75 patients were followed up for 1-45 months, with a median postoperative follow-up period of 18 months. The 1-year survival rate of the patients was 78.58%, and the 2-year survival rate was 67.40%. Log-rank survival analysis showed difference in overall survival between the non-intestinal-type adenocarcinoma group (pancreaticobiliary-type adenocarcinoma and tubular adenocarcinoma) and the intestinal-type adenocarcinoma group (P=0.0415). There was also statistical difference in the overall survival between the CK7 positive group and the CK7 negative group of tumor cells (P=0.0425). Conclusions: AA occurres frequently in the elderly and there is no significant gender difference. Pancreatobiliary-type carcinoma and tubular adenocarcinoma are dominant histological types, and intestinal-type adenocarcinoma accounts for only a small portion. Non intestinal-type adenocarcinoma and CK7 positivity are risk factors for poor prognosis of AA.

Cite this article

LI Lei, YUAN Fei, WANG Chaofu, XU Haimin, WANG Ting . Ampullary adenocarcinoma: analysis of the clinicopathological features and prognostic factors[J]. Journal of Diagnostics Concepts & Practice, 2022 , 21(03) : 355 -361 . DOI: 10.16150/j.1671-2870.2022.03.011

References

[1] Nagtegaal ID, Odze RD, Klimstra D, et al. The 2019 WHO classification of tumours of the digestive system[J]. Histopathology, 2020, 76(2):182-188.
[2] Chang DK, Jamieson NB, Johns AL, et al. Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater[J]. J Clin Oncol, 2013, 31(10):1348-1356.
[3] Asano E, Okano K, Oshima M, et al. Phenotypic characterization and clinical outcome in ampullary adenocarcinoma[J]. J Surg Oncol, 2016, 114(1):119-127.
[4] Fernandez-Placencia RM, Montenegro P, Guerrero M, et al. Survival after curative pancreaticoduodenectomy for ampullary adenocarcinoma in a South American population: A retrospective cohort study[J]. World J Gastrointest Surg, 2022, 14(1):24-35.
[5] Palmeri M, Funel N, Franco GD, et al. Tissue microarray-chip featuring computerized immunophenotypical characterization more accurately subtypes ampullary adenocarcinoma than routine histology[J]. World J Gastroenterol, 2020, 26(43):6822-6836.
[6] Harthimmer MR, Stolborg U, Pfeiffer P, et al. Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas[J]. J Clin Pathol, 2019, 72(11):762-770.
[7] Zakaria H, Sallam AN, Ayoub II, et al. Prognostic factors for long-term survival after pancreaticoduodenectomy for periampullary adenocarcinoma. A retrospective cohort study[J]. Ann Med Surg (Lond), 2020, 57:321-327.
[8] Jayaramayya K, Balachandar V, Santhy KS. Ampullary carcinoma-A genetic perspective[J]. Mutat Res Rev Mutat Res, 2018, 776:10-22.
[9] Paluri R, Kasi A. Ampullary Cancer[R/OL]. Treasure Island (FL): StatPearls Publishing,2022-04-06. https://pubmed.ncbi.nlm.nih.gov/32310418/.
[10] Zhang X, Sun C, Li Z, et al. Development and Validation of a New Lymph Node Ratio-Based Staging System for Ampullary Carcinoma After Curative Pancreaticoduodenectomy[J]. Front Oncol, 2022, 11:811595.
[11] Matsui S, Yamamoto Y, Sugiura T, et al. The Prognostic Relevance of the Number and Location of Positive Lymph Nodes for Ampulla of Vater Carcinoma[J]. World J Surg, 2021, 45(1):270-278.
[12] Moekotte AL, van Roessel S, Malleo G, et al. Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma[J]. Eur J Surg Oncol, 2020, 46(9):1717-1726.
[13] Sánchez-García J, Candanedo-González F, Félix-Félix AK, et al.: Retrospective cohort of pancreatic and Vater ampullary adenocarcinoma from a reference center in Mexico[J]. Ann Med Surg (Lond), 2018, 30:7-12.
[14] Chen SC, Shyr YM, Wang SE. Longterm survival after pancreaticoduodenectomy for periampullary adenocarcinomas[J]. HPB (Oxford), 2013, 15(12):951-957.
[15] Perysinakis I, Minaidou E, Leontara V, et al. Differential Expression of β-Catenin, EGFR, CK7, CK20, MUC1, MUC2, and CDX 2 in Intestinal and Pancreatobiliary-Type Ampullary Carcinomas[J]. Int J Surg Pathol, 2017, 25(1):31-40.
[16] Zhou Y, Li D, Wu L, et al. The histopathologic type predicts survival of patients with ampullary carcinoma after resection: A meta-analysis[J]. Pancreatology, 2017, 17(2):273-278.
[17] Alkhasawneh A, Duckworth LV, George TJ, et al. Clinical, morphologic, and immunophenotypic characteristics of ampullary carcinomas with an emphasis on SMAD4 expression[J]. J Gastrointest Oncol, 2016, 7(6):974-981.
[18] Bolm L, Ohrner K, Nappo G, et al. Adjuvant therapy is associated with improved overall survival in patients with pancreatobiliary or mixed subtype ampullary cancer after pancreatoduodenectomy - A multicenter cohort study[J]. Pancreatology, 2020, 20(3):433-441.
[19] Xia T, Wu X, Mou Y, et al. Clinicopathological Prognostic Factors and Chemotherapeutic Outcome for Two Histopathological Types of Ampulla of Vater Adenocarcinoma[J]. Front Oncol, 2021, 11:616108.
[20] Yoo YJ, Kang CM, Choi M, et al. Preoperative prognostic nutritional index as an independent prognostic factor for resected ampulla of Vater cancer[J]. PLoS One, 2020, 15(3):e0229597.
[21] Zhao X, Dong J, Huang X, et al. Prognostic factors for survival of patients with ampullary carcinoma after local resection[J]. ANZ J Surg, 2015, 85(7-8):567-571.
[22] Bronsert P, Kohler I, Werner M, et al. Intestinal-type of differentiation predicts favourable overall survival: confirmatory clinicopathological analysis of 198 periampullary adenocarcinomas of pancreatic, biliary, ampullary and duodenal origin[J]. BMC Cancer, 2013, 13:428.
[23] Park HM, Park SJ, Han SS, et al. Very early recurrence following pancreaticoduodenectomy in patients with ampullary cancer[J]. Medicine (Baltimore), 2019, 98(44):e17711.
Outlines

/